Month: April 2021

Aktieägarna i NGS Group AB (publ) höll den 23 april 2021 kl. 15:00 årsstämma varvid i huvudsak följande beslut fattades. • Resultaträkningen och balansräkningen samt koncernresultaträkningen och koncernbalansräkningen för räkenskapsåret 2020 fastställdes. • Beslutades att ingen utdelning lämnas till aktieägare för räkenskapsåret 2020 och att den ansamlade vinsten om 121 298 237 kr balanseras i ny räkning. • Styrelsens ledamöter och verkställande direktören beviljades ansvarsfrihet för deras förvaltning under räkenskapsåret 2020. • Det beslutades att styrelsearvode ska utgå med 100 000 kr till vardera ordinarie styrelseledamot och 200 000 kr till styrelsens ordförande. Det beslutades att arvode för ledamöter i revisionsutskottet ska utgå med 25 000 kronor per ledamot. Inget arvode, utöver styrelsearvodet, ska utgå till ledamöter i ersättningsutskottet....

Nilörngruppen AB publicerade idag Årsredovisning och Hållbarhetsrapport för 2020 på bolagets webbplats, www.nilorn.se. Borås den 23 april 2021 Vid frågor kontakta: Krister MagnussonCEOM: +46 704 852 114E: krister.magnusson@nilorn.com Denna information är sådan som Nilörngruppen AB är skyldigt att offentliggöra enligt lagen om värdepappersmarknaden. Informationen lämnades för offentliggörande den 23/4 2021 kl. 16,00 CET. Bilagor

SmallCap Danmark A/S (CVR nr. 39703416) afholdte fredag d. 23. april 2021 kl. 16.00 ordinær generalforsamling. Indkaldelse, dagsorden og de fuldstændige forslag fremgår af selskabets børsmeddelelse nr. 06.2021 af d. 31. marts 2021. Bestyrelsen havde udpeget advokat Jens Ahrendt, Mazanti-Andersen Advokatpartner­selskab til dirigent. Dirigenten konstaterede, at general­for­samlingen var rettidigt varslet og beslutnings­dygtig. Dagsordenspunkt 1, Bestyrelsens beretning om selskabets forhold i 2020Bestyrelsesformand Peter Ott redegjorde for udviklingen i 2020 i hovedtræk. Forud for generalforsamlingen havde selskabet offentliggjort delårs­rapport for 1. kvartal 2021. Peter Ott opsummerede kort meddelelsens indhold, og redegjorde herunder for resultatudviklingen i 1. kvartal 2021 i hovedtal. Beretningen blev taget til efterretning. Dagsordenspunkt...

        New Dupixent®(dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 yearsNearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AADPARIS – April 23, 2021 – New analyses from Dupixent® (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Additional analyses evaluated response rates across a broad population, and the impact of Dupixent on...

De nouvelles analyses des données relatives à Dupixent®(dupilumab) confortent son profil de sécurité et d’efficacité à long terme chez les patients atteints de dermatite atopique, dès l’âge de 6 ans        Près de 30 présentations de données obtenues dans le cadre d’essais cliniques et en vie réelle aux congrès de l’AAD et de l’ESPD, dont des données de l’impact de Dupixent sur les indicateurs de la dermatite atopique modérée à sévère non contrôlée. Congrès de l’AAD : présentation de dernière heure des données de phase II du rilzabrutinib, un médicament expérimental pour le traitement du pemphigus vulgaire – une maladie auto-immune rare et invalidante.PARIS – Le 23 avril 2021 – De nouvelles analyses des données des essais cliniques consacrés à Dupixent® (dupilumab) ont permis de faire ressortir une réduction de l’incidence des infections...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OTTAWA, April 23, 2021 (GLOBE NEWSWIRE) — Leonovus Inc. (TSXV:LTV) (the “Company” or “Leonovus”), announces that it has amended certain terms of its public offering, that was previously announced on March 29, 2021 (the “Offering”). Pursuant to the amended terms, the Offering of units of the Company (the “Units”) will be conducted at a price of $0.56 per Unit (the “Offering Price”) for minimum gross proceeds of $2,500,000 and maximum gross proceeds of $4,000,000. Each Unit shall be comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”). Each Warrant is exercisable into one Common...

Detailed results from Phase 2b study of roflumilast foam in scalp and body psoriasis featured in late-breaking oral presentation Data demonstrate roflumilast foam was well-tolerated and improved scalp and body psoriasis as early as two weeks after treatment initiation Four additional posters feature data that support roflumilast foam for the treatment of seborrheic dermatitis and roflumilast cream for mild-to- severe chronic plaque psoriasisWESTLAKE VILLAGE, Calif., April 23, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the presentation of new data demonstrating the safety and efficacy of roflumilast...

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity through the 48 weeks of treatment Data presented today in a late-breaking oral presentation at AAD VMX 2021 Management to host an investor call today at 12:00 p.m. EDT BOULDER, Colo., April 23, 2021 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced results from its Phase 3 open-label, long-term safety study (“ARGYLE” or “LTSS”), which were also presented today in a late-breaking oral presentation at the American Academy...

ISELIN, N.J., April 23, 2021 (GLOBE NEWSWIRE) — Middlesex Water Company (NASDAQ:MSEX) announced today that its Board of Directors has declared a cash dividend of $0.2725 per share on its common stock payable on June 1, 2021 to holders of record as of May 14, 2021. Middlesex Water has paid cash dividends in varying amounts continually since 1912 and has increased its annual dividend rate for 48 consecutive years. The Company began mailing its Annual Meeting materials on April 12, 2021. Due to health concerns surrounding COVID-19 and to support the health and well-being of participants, Middlesex Water Company’s Annual Meeting of Shareholders will be held on May 25, 2021 at 11:00 a.m. EDT via webcast only. Shareholders will be able to participate in the Annual Meeting by visiting http://www.virtualshareholdermeeting.com/MSEX2021 and...

Vancouver, British Columbia, April 23, 2021 (GLOBE NEWSWIRE) — St. James Gold Corp. (TSX-V: LORD) (OTC: LRDJF)(FSE: BVU3) the “Company” is pleased to announce the appointment of its technical advisory team and formation of a technical committee in anticipation of upcoming gold exploration activities on its option on the Florin Gold Project in the Yukon Territory, Canada and its projects in Quinn Lake and Grub Line located in Newfoundland and Labrador, Canada. In total, these two team members alongside our VP of Exploration, Stewart Jackson and the three members from the Florin Gold Project’s technical team, bring over 100 years of exploration and mining experience. These appointments represent a key advancement to overseeing drill budgeting in the Yukon and Newfoundland as the Company prepares for an active 2021 exploration season. The...